---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-211922"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:33:45.830846+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Q1 net loss $9.1M ($0.54/sh); cash $226.6M; HPI opt-in decision pending mid-2026

## Summary
- Net loss $9.1M ($0.54/share) vs $8.8M ($1.17/share) in Q1 2025; cash $226.6M at quarter end.
- Gilead collaboration revenue $8.2M, down from $9.4M YoY; R&D expenses flat at $14.9M.
- Completed Phase 1b for ABI-5366/1179 (genital herpes); to decide on 40% U.S. cost-profit share opt-in by mid-2026.
- Completed chronic tox for ABI-6250 (HDV entry inhibitor); Phase 2 start expected Q4 2026.
- Cash runway projected into 2028.

## SEC filing metadata
- accession: 0001193125-26-211922
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/0001193125-26-211922-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/asmb-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-211922
- JSON: https://secwatch.observer/filing/0001193125-26-211922.json
- Plain text: https://secwatch.observer/filing/0001193125-26-211922.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported the quarter ended March 31, 2026 results: revenue $8.2 million, net income Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share, EPS $0.54 per basic and diluted share.
  - Period: the quarter ended March 31, 2026
  - Revenue: $8.2 million
  - Net income: Net loss attributable to common stockholders was $9.1 million, or $0.54 per basic and diluted share
  - EPS: $0.54 per basic and diluted share
  - Result: reported results
  source text: compared to $248.1 million as of December 31, 2025. The company’s cash position is projected to fund operations into 2028. • Revenue from collaborative research with Gilead was $8.2 million for the three months ended March 31, 2026, compared to $9.4 million for the same period in 2025. The decrease reflects the timing of activities performed and progress toward
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000119312526211922/0001193125-26-211922-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.